TG Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 61.18 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 8.68B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab ...